Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma | PHASE1 | NOT YET_RECRUITING | 34 | — | — | Sep 1, 2022 | Mar 1, 2027 | Aug 12, 2022 | 1 | China |
An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment
Dose-limiting toxicity (DLT) refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose
RP2D established through ATD+BOIN design
CAR positive NK cells in peripheral blood and bone marrow after LUCAR-B68 infusion
CAR transgene levels in peripheral blood after LUCAR-B68 infusion
| Arm | Type | Description |
|---|---|---|
| LUCAR-B68 cells product | EXPERIMENTAL | Each subject will receive LUCAR-B68 cells |
| Name | Type | Description |
|---|---|---|
| LUCAR-B68 cells product | BIOLOGICAL | Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen |
Inclusion Criteria: 1. The subject voluntarily participates in the clinical study; Fully understand and be Informed of the study and sign the Informed consent (Informed Consent Form, ICF); Willing to follow and able to complete all test procedures; Informed consent must be obtained before initiatin...